[HTML][HTML] A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe …
M Gatti, M Bartoletti, PG Cojutti, P Gaibani… - Journal of Global …, 2021 - Elsevier
Objectives The aim of this study was to explore the relationship between cefiderocol
pharmacokinetic/pharmacodynamic (PK/PD) target attainment and microbiological outcome …
pharmacokinetic/pharmacodynamic (PK/PD) target attainment and microbiological outcome …
Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis
D Luque-Paz, Y Bennis, P Jaubert… - Journal of …, 2022 - academic.oup.com
Cefiderocol is a new injectable siderophore cephalosporin antibiotic with an extended Gram-
negative activity spectrum including carbapenem-resistant bacteria. It was approved by the …
negative activity spectrum including carbapenem-resistant bacteria. It was approved by the …
Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry …
B Llopis, A Bleibtreu, D Schlemmer… - Clinical Chemistry and …, 2021 - degruyter.com
Objectives Cefiderocol and ceftobiprole are new generation cephalosporin antibiotics that
exhibit high inter-individual plasma concentration variability that potentially impact their …
exhibit high inter-individual plasma concentration variability that potentially impact their …
Fast and sensitive analysis of cefiderocol in human plasma microsamples by liquid chromatography-isotope dilution tandem mass spectrometry for therapeutic drug …
Cefiderocol (C) is a parenteral siderophore cephalosporin with relevant inter-individual
pharmacokinetic variability among critically ill patients, which may potentially affect effective …
pharmacokinetic variability among critically ill patients, which may potentially affect effective …
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI …
M Gatti, M Bartoletti, PG Cojutti, P Gaibani… - Journal of Global …, 2021 - cris.unibo.it
To explore the relationship between cefiderocol pharmacokinetic/pharmacodynamic
(PK/PD) target attainment and microbiological outcome in critically ill patients affected by …
(PK/PD) target attainment and microbiological outcome in critically ill patients affected by …
Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support
M Marín-Cerezuela, R Martín-Latorre, J Frasquet… - Critical Care, 2024 - Springer
Extracorporeal membrane oxygenation (ECMO) is increasingly being used as a rescue
therapy for severe acute respiratory distress syndrome or severe circulatory failure …
therapy for severe acute respiratory distress syndrome or severe circulatory failure …
Optimizing Cefiderocol Dosing Through Population Pharmacokinetic/Pharmacodynamic Simulation: An Assessment of Drug Cost Reductions
K Oda, H Jono, H Saito - Therapeutic Drug Monitoring, 2022 - journals.lww.com
Background: Cefiderocol is a siderophore cephalosporin antibiotic with bactericidal activity
against carbapenem-resistant Enterobacterales. However, an efficient dosing strategy is yet …
against carbapenem-resistant Enterobacterales. However, an efficient dosing strategy is yet …
Optimización del análisis de antibióticos de uso en humanos y determinación de sus niveles en diferentes muestras de interés clínico.
MT Villalta Palmer, E Gálvez Buerba, J Pardo Jimeno - zaguan.unizar.es
La resistencia bacteriana a antibióticos se ha convertido en un problema de salud pública
cada vez más compleja, que ha dado lugar a que en la actualidad se haya restringido …
cada vez más compleja, que ha dado lugar a que en la actualidad se haya restringido …
[引用][C] Revisión bibliográfica de la técnica de Cromatografía Liquida de Alta Resolución (CLAR) para el análisis y separación de nuevas moléculas con actividad …
JÁ Rosas, KR Villar